Skip to Content
Merck
  • Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors.

Identification and Structure-Activity Relationship of HDAC6 Zinc-Finger Ubiquitin Binding Domain Inhibitors.

Journal of medicinal chemistry (2018-05-10)
Renato Ferreira de Freitas, Rachel J Harding, Ivan Franzoni, Mani Ravichandran, Mandeep K Mann, Hui Ouyang, Mark Lautens, Vijayaratnam Santhakumar, Cheryl H Arrowsmith, Matthieu Schapira
ABSTRACT

HDAC6 plays a central role in the recruitment of protein aggregates for lysosomal degradation and is a promising target for combination therapy with proteasome inhibitors in multiple myeloma. Pharmacologically displacing ubiquitin from the zinc-finger ubiquitin-binding domain (ZnF-UBD) of HDAC6 is an underexplored alternative to catalytic inhibition. Here, we present the discovery of an HDAC6 ZnF-UBD-focused chemical series and its progression from virtual screening hits to low micromolar inhibitors. A carboxylate mimicking the C-terminal extremity of ubiquitin, and an extended aromatic system stacking with W1182 and R1155, are necessary for activity. One of the compounds induced a conformational remodeling of the binding site where the primary binding pocket opens up onto a ligand-able secondary pocket that may be exploited to increase potency. The preliminary structure-activity relationship accompanied by nine crystal structures should enable further optimization into a chemical probe to investigate the merit of targeting the ZnF-UBD of HDAC6 in multiple myeloma and other diseases.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
SGC-UBD253N, ≥98% (HPLC)
Sigma-Aldrich
SGC-UBD253, ≥98% (HPLC)